Scott Alexander, curated
← Back to curation

Sleep – Now By Prescription

Quality
60
Strong
Claude Shift
20
Slight
RWI
2
of 10

Summary

A case study of the previous post's thesis: Ramelteon, a ~$100/month patented drug, merely mimics melatonin, a cheap OTC hormone hospitals don't even stock because no company had reason to push it - Scott ends up bringing melatonin from his own bathroom. Rounded out with practical melatonin/circadian facts (dosing, beta-blocker timing, agomelatine).

Why this score

Quality 60 · Strong. Tight, informative, practically useful, with a sharp illustrative anecdote, but narrow in scope. Low-Strong.

Claude’s paradigm shift 20 · Slight. Illustrates the pharma-incentive point rather than advancing a new idea; essentially practical/explanatory. Slight.

Real-world impact 2 · Minor. A case study of the drug-officialization thesis (patented Ramelteon vs cheap OTC melatonin) with practical dosing facts; informative within the discourse but narrow, with no policy or practice change → RWI 2.